{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06108063",
            "orgStudyIdInfo": {
                "id": "2023-194"
            },
            "organization": {
                "fullName": "Steadman Philippon Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan",
            "officialTitle": "Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan",
            "therapeuticArea": [
                "Other"
            ],
            "study": "mitigation-of-arthrofibrosis-after-total-knee-arthroplasty-using-losartan"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-23",
            "studyFirstSubmitQcDate": "2023-10-26",
            "studyFirstPostDateStruct": {
                "date": "2023-10-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Steadman Philippon Research Institute",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.",
            "detailedDescription": "This is a double-blind, randomized, placebo-controlled clinical trial proposed to evaluate the efficacy and safety of Losartan for reducing or preventing arthrofibrosis and improving patient-reported outcomes after total knee arthroplasty (TKA). Fibrosis will be evaluated over time after TKA using measures of knee range of motion and capsular thickening.\n\n120 patients scheduled to undergo total knee arthroplasty will be recruited from the clinical practice of the Principal Clinical Investigator or his designee at The Steadman Clinic (TSC) and randomized into one of two arms (1:1)."
        },
        "conditionsModule": {
            "conditions": [
                "Knee Arthroplasty, Total"
            ],
            "keywords": [
                "TKA Losartan Arthrofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "prospective, randomized, double-blind, placebo controlled clinical trial",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "The Investigator or properly trained and delegated study team member (Physician Assistant) will write the prescription for the study medication. The subject's randomization number will be communicated directly to the Vail Health pharmacy. The Vail Health pharmacy will maintain an unblinded, de-identified randomization spreadsheet that documents group allocation for each subject. The Vail Health Pharmacy oversees and manages drug disbursement for research.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 120,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Losartan (investigational)",
                    "type": "EXPERIMENTAL",
                    "description": "Losartan 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).",
                    "interventionNames": [
                        "Drug: Losartan"
                    ]
                },
                {
                    "label": "Placebo (control)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Losartan Placebo 12.5 mg, PO, BID, for four weeks post-TKA surgery (on Days 1 through 28, starting the day after surgery).",
                    "interventionNames": [
                        "Drug: Placebo - Losartan"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Losartan",
                    "description": "12.5 mg oral Losartan taken for 28 days total (4 week postoperative).",
                    "armGroupLabels": [
                        "Losartan (investigational)"
                    ],
                    "otherNames": [
                        "Losartan potassium"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo - Losartan",
                    "description": "Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).",
                    "armGroupLabels": [
                        "Placebo (control)"
                    ],
                    "otherNames": [
                        "Placebo Oral Tablet"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Quantitative Ultrasound Measurement of Capsular Thickness at Lateral Retinaculum",
                    "description": "Thickness of knee joint capsule will be measured using quantitative ultrasound. The thickness will be measured using the distance between the two bright echoes seen on the ultrasound image that correspond to the superficial and deep edges of the capsule.",
                    "timeFrame": "Baseline, 6 weeks post-op, and 3 months post-op"
                },
                {
                    "measure": "Knee Range of Motion",
                    "description": "Reported as degree of knee Flexion/Extension",
                    "timeFrame": "Baseline, 6 weeks post-op, and 3 months post-op"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "Occurrence of adverse events",
                    "timeFrame": "From date of study drug dosing until the end of the study, an average of 3.5 months"
                },
                {
                    "measure": "TGF-\u00df multiplex immunoassay assessment of peripheral blood plasma/serum",
                    "description": "Biomarkers assessed will include quantifying secreted proteins related to inflammation, fibrosis, and senescence in the non-cellular fraction of the blood (e.g., serum and/or plasma) using commercially available immunocapture assays.",
                    "timeFrame": "Baseline, 10-17 days post-op, 6 weeks post-op, and 3 months post-op"
                },
                {
                    "measure": "Flow cytometry immunosenescent phenotyping assessment of peripheral blood mononuclear cells",
                    "description": "Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels.",
                    "timeFrame": "Baseline, 10-17 days post-op, 6 weeks post-op, and 3 months post-op"
                },
                {
                    "measure": "Knee Extensor Isometric Strength Assessment",
                    "description": "Assessed via handheld dynamometer and inclinometer containing a load cell that will digitally record the knee extension force.",
                    "timeFrame": "Baseline, and 3 months post-op"
                },
                {
                    "measure": "Patient Reported Outcomes Questionnaire-Numeric Rating Scale for Knee Pain",
                    "description": "Scale from 1-10. Higher score represents greater knee pain.",
                    "timeFrame": "Baseline, day of surgery, 10-17 days post-op, 6 weeks post-op, and 3 months post-op"
                },
                {
                    "measure": "Patient Reported Outcomes Questionnaire-Western Ontario and McMaster Universities",
                    "description": "Scale from 0-96. Higher score represents worse knee health.",
                    "timeFrame": "Baseline, and 3 months post-op"
                },
                {
                    "measure": "Patient Reported Outcomes Questionnaire-Veteran's Rand 12-Item Health Survey",
                    "description": "Includes two subscales to calculate the total score. Higher score represents greater health. Scale standardized to a US Population mean of 50 and standard deviation of 10 points.",
                    "timeFrame": "Baseline, and 3 months post-op"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Planned primary total knee arthroplasty of a single knee;\n2. Male or female \u2265 18 years of age;\n3. Capacity to personally give informed consent (consent via legally authorized representative will not be accepted) and who are willing to comply with all study-related procedures and assessments.\n\nExclusion Criteria:\n\n1. Breastfeeding, pregnant, or planning to become pregnant during participation in the study;\n2. Diagnosed with inflammatory or other arthritis caused by autoimmune disease affecting the study knee;\n3. Previous knee arthroplasty on the study knee;\n4. Previous infection affecting the study knee;\n5. Planned total knee arthroplasty of contralateral knee to occur at any point during the study participation period;\n6. Are hypotensive as confirmed by Principal Clinical Investigator or appropriate designee;\n7. Planned lower extremity surgery (other than TKA in the study leg) for the duration of study participation;\n8. Any condition other than knee osteoarthritis that significantly impairs ability to walk or perform other activities of daily living;\n9. Currently taking: Losartan or other medication in the same drug class; Warfarin or related anticoagulants;\n10. Opioid analgesics taken in the past 8 weeks and are not willing to discontinue these medications through the duration of the study (except as prescribed as standard of care in the immediate post-operative period);\n11. Allergic to any active or inactive ingredient of Losartan;\n12. Taking medication with known adverse Losartan interaction;\n13. Subjects that have any medical condition, including malignancies, laboratory findings, and/or findings in the medical history or in the pre-study assessments that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation, or prevent the patient from fully participating in all aspects of the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Suzanne L Page, JD",
                    "role": "CONTACT",
                    "phone": "970-401-8770",
                    "email": "spage@sprivail.org"
                },
                {
                    "name": "Luz Thede",
                    "role": "CONTACT",
                    "phone": "970-409-7566",
                    "email": "lthede@sprivail.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Johnny Huard, PhD",
                    "affiliation": "Steadman Philippon Research Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Scott Tashman, PhD",
                    "affiliation": "Steadman Philippon Research Institute",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The Steadman Clinic",
                    "status": "RECRUITING",
                    "city": "Vail",
                    "state": "Colorado",
                    "zip": "81657",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Suzanne L Page, JD",
                            "role": "CONTACT",
                            "phone": "970-401-8770",
                            "email": "spage@sprivail.org"
                        },
                        {
                            "name": "Luz Thede",
                            "role": "CONTACT",
                            "phone": "970-409-7566",
                            "email": "lthede@sprivail.org"
                        },
                        {
                            "name": "Raymond Kim, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.64026,
                        "lon": -106.3742
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019808",
                    "term": "Losartan"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000889",
                    "term": "Anti-Arrhythmia Agents"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000047228",
                    "term": "Angiotensin II Type 1 Receptor Blockers"
                },
                {
                    "id": "D000057911",
                    "term": "Angiotensin Receptor Antagonists"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21701",
                    "name": "Losartan",
                    "asFound": "Core",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4213",
                    "name": "Anti-Arrhythmia Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4132",
                    "name": "Angiotensin II",
                    "relevance": "LOW"
                },
                {
                    "id": "M289354",
                    "name": "Giapreza",
                    "relevance": "LOW"
                },
                {
                    "id": "M4135",
                    "name": "Angiotensinogen",
                    "relevance": "LOW"
                },
                {
                    "id": "M25789",
                    "name": "Angiotensin II Type 1 Receptor Blockers",
                    "relevance": "LOW"
                },
                {
                    "id": "M28916",
                    "name": "Angiotensin Receptor Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                }
            ]
        }
    },
    "hasResults": false
}